Contact this trialFirst, we need to learn more about you.
Anti-metabolites
AK112 for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 3
Fargo, North Dakota
"This trial is testing a new drug, AK112, in combination with standard chemotherapy in patients with a specific type of lung cancer who have not responded to previous treatments."
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service